{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T10:20:37Z","timestamp":1780050037064,"version":"3.53.1"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82003875"],"award-info":[{"award-number":["82003875"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81673521"],"award-info":[{"award-number":["81673521"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872942"],"award-info":[{"award-number":["81872942"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970133"],"award-info":[{"award-number":["81970133"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Postdoctoral Advanced Programs of Zhejiang Province","award":["ZJ2020154"],"award-info":[{"award-number":["ZJ2020154"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.taap.2020.115299","type":"journal-article","created":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T01:04:38Z","timestamp":1603155878000},"page":"115299","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["Balance between the toxicity and anticancer activity of arsenic trioxide in treatment of acute promyelocytic leukemia"],"prefix":"10.1016","volume":"409","author":[{"given":"Qian Qian","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao Ying","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Naranmandura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Hu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.taap.2020.115299_bb0005","doi-asserted-by":"crossref","first-page":"6535","DOI":"10.1182\/blood-2011-05-354530","article-title":"Oral arsenic trioxide-based maintenance regimens for first complete remission of acute promyelocytic leukemia: a 10-year follow-up study","volume":"118","author":"Au","year":"2011","journal-title":"Blood."},{"issue":"8","key":"10.1016\/j.taap.2020.115299_bb0010","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1124\/dmd.117.079640","article-title":"Multidrug resistance protein 1 (MRP1\/ABCC1)-mediated cellular protection and transport of methylated arsenic metabolites differs between human cell lines","volume":"46","author":"Banerjee","year":"2018","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.taap.2020.115299_bb0015","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/978-3-540-79885-9_16","article-title":"Aquaglyceroporins and metalloid transport: implications in human diseases","volume":"190","author":"Bhattacharjee","year":"2009","journal-title":"Handb. Exp. Pharmacol."},{"issue":"2","key":"10.1016\/j.taap.2020.115299_bb0020","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/17474086.2019.1562332","article-title":"Intravenous arsenic trioxide and all-trans retinoic acid as front-line therapy for low-risk acute promyelocytic leukemia","volume":"12","author":"Breccia","year":"2019","journal-title":"Expert. Rev. Hematol."},{"issue":"10","key":"10.1016\/j.taap.2020.115299_bb0025","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.3390\/ijms19103210","article-title":"Aquaporins alteration profiles revealed different actions of Senna, Sennosides, and Sennoside a in diarrhea-rats","volume":"19","author":"Cao","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.taap.2020.115299_bb0030","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1056\/NEJMe1304762","article-title":"Targeting agents alone to cure acute promyelocytic leukemia","volume":"369","author":"Chen","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.taap.2020.115299_bb0035","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1007\/s00216-012-6700-5","article-title":"Arsenic speciation in saliva of acute promyelocytic leukemia patients undergoing arsenic trioxide treatment","volume":"405","author":"Chen","year":"2013","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.taap.2020.115299_bb0040","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.talanta.2018.03.021","article-title":"Arsenic speciation in hair and nails of acute promyelocytic leukemia (APL) patients undergoing arsenic trioxide treatment","volume":"184","author":"Chen","year":"2018","journal-title":"Talanta."},{"key":"10.1016\/j.taap.2020.115299_bb0045","first-page":"4938797","article-title":"Bradycardia during induction therapy with all-trans retinoic acid in patients with acute Promyelocytic leukemia: case report and literature review","volume":"2018","author":"Chen","year":"2018","journal-title":"Case Rep. Hematol."},{"issue":"10","key":"10.1016\/j.taap.2020.115299_bb0050","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1007\/s00277-018-3400-z","article-title":"Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy","volume":"97","author":"Cicconi","year":"2018","journal-title":"Ann. Hematol."},{"issue":"4\u20135","key":"10.1016\/j.taap.2020.115299_bb0055","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.blre.2010.04.001","article-title":"Arsenic trioxide - an old drug rediscovered","volume":"24","author":"Emadi","year":"2010","journal-title":"Blood Rev."},{"issue":"2","key":"10.1016\/j.taap.2020.115299_bb0060","first-page":"229","article-title":"Clinical pharmacokinetics and safety profile of single agent arsenic trioxide by continuous slow-rate infusion in patients with newly diagnosed acute promyelocytic leukemia. Cancer Chemother","volume":"82","author":"Gao","year":"2018","journal-title":"Pharmacol."},{"issue":"11","key":"10.1016\/j.taap.2020.115299_bb0065","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1002\/cncr.31327","article-title":"Long-term outcome of relapsed acute promyelocytic leukemia treated with oral arsenic trioxide-based reinduction and maintenance regimens: a 15-year prospective study","volume":"124","author":"Gill","year":"2018","journal-title":"Cancer."},{"issue":"8","key":"10.1016\/j.taap.2020.115299_bb0070","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1007\/s00204-020-02772-9","article-title":"Biotransformation of arsenic and toxicological implication of arsenic metabolites","volume":"94","author":"Hirano","year":"2020","journal-title":"Arch. Toxicol."},{"issue":"3","key":"10.1016\/j.taap.2020.115299_bb0075","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00775-018-1537-9","article-title":"Arsenic trioxide: insights into its evolution to an anticancer agent","volume":"23","author":"Hoonjan","year":"2018","journal-title":"J. Biol. Inorg. Chem."},{"issue":"4","key":"10.1016\/j.taap.2020.115299_bb0080","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1080\/09603123.2014.958139","article-title":"The health effects of exposure to arsenic-contaminated drinking water: a review by global geographical distribution","volume":"25","author":"Huang","year":"2015","journal-title":"Int. J. Environ. Health Res."},{"issue":"3","key":"10.1016\/j.taap.2020.115299_bb0085","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1039\/B920471G","article-title":"Trivalent arsenicals and glucose use different translocation pathways in mammalian GLUT1","volume":"2","author":"Jiang","year":"2010","journal-title":"Metallomics."},{"issue":"43","key":"10.1016\/j.taap.2020.115299_bb0090","doi-asserted-by":"crossref","first-page":"33404","DOI":"10.1074\/jbc.M007030200","article-title":"The MRP2\/cMOAT transporter and arsenic-glutathione complex formation are required for biliary excretion of arsenic","volume":"275","author":"Kala","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.taap.2020.115299_bb0095","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s40572-014-0040-x","article-title":"Drinking water arsenic contamination, skin lesions, and malignancies: a systematic review of the global evidence","volume":"2","author":"Karagas","year":"2015","journal-title":"Curr. Environ. Health Rep."},{"issue":"4","key":"10.1016\/j.taap.2020.115299_bb0100","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/bjh.15153","article-title":"Early detection of differentiation syndrome by chest ultrasound in acute promyelocytic leukaemia","volume":"184","author":"Karunakaran","year":"2019","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.taap.2020.115299_bb0105","doi-asserted-by":"crossref","unstructured":"Khairul, I., Wang, Q. Q., Jiang, Y. H., Wang, C., Naranmandura, H., 2017. Metabolism, toxicity and anticancer activities of arsenic compounds. Oncotarget. 8(14), 23905\u201323926. Doi:10.18632\/oncotarget.14733.","DOI":"10.18632\/oncotarget.14733"},{"issue":"8","key":"10.1016\/j.taap.2020.115299_bb0110","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00228-002-0514-x","article-title":"Systemic availability of arsenic from oral arsenic-trioxide used to treat patients with hematological malignancies","volume":"58","author":"Kumana","year":"2002","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.taap.2020.115299_bb0115","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.molmed.2011.10.001","article-title":"Curing APL through PML\/RARA degradation by As2O3","volume":"18","author":"Lallemand-Breitenbach","year":"2012","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.taap.2020.115299_bb0120","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jinorgbio.2011.11.009","article-title":"Arsenic-glutathione conjugate transport by the human multidrug resistance proteins (MRPs\/ABCCs)","volume":"108","author":"Leslie","year":"2012","journal-title":"J. Inorg. Biochem."},{"issue":"5","key":"10.1016\/j.taap.2020.115299_bb0125","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1369\/0022155416641028","article-title":"A systematic characterization of Aquaporin-9 expression in human Normal and pathological tissues","volume":"64","author":"Lindskog","year":"2016","journal-title":"J. Histochem. Cytochem."},{"issue":"4","key":"10.1016\/j.taap.2020.115299_bb0130","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.bbrc.2004.03.003","article-title":"Arsenic trioxide uptake by human and rat aquaglyceroporins","volume":"316","author":"Liu","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.taap.2020.115299_bb0135","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.bbrc.2006.10.054","article-title":"Mammalian glucose permease GLUT1 facilitates transport of arsenic trioxide and methylarsonous acid","volume":"351","author":"Liu","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.taap.2020.115299_bb0140","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1300874","article-title":"Retinoic acid and arsenic trioxide for acute promyelocytic leukemia","volume":"369","author":"Lo-Coco","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.taap.2020.115299_bb0145","first-page":"1472","article-title":"Treatment of acute promyelocytic leukemia","volume":"369","author":"Lo-Coco","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.taap.2020.115299_bb0150","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1039\/C8MT00057C","article-title":"Role of arsenic (+3 oxidation state) methyltransferase in arsenic mediated APL treatment: an in vitro investigation","volume":"10","author":"Maimaitiyiming","year":"2018","journal-title":"Metallomics."},{"issue":"3","key":"10.1016\/j.taap.2020.115299_bb0155","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/03602532.2020.1791173","article-title":"Biotransformation of arsenic trioxide by AS3MT favors eradication of acute promyelocytic leukemia: revealing the hidden facts","volume":"52","author":"Maimaitiyiming","year":"2020","journal-title":"Drug Metab. Rev."},{"issue":"3","key":"10.1016\/j.taap.2020.115299_bb0160","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.taap.2003.10.030","article-title":"Speciation of arsenic in biological samples","volume":"198","author":"Mandal","year":"2004","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"5","key":"10.1016\/j.taap.2020.115299_bb0165","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/sj.leu.2404165","article-title":"Hepatotoxicity profile of single agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia, its impact on clinical outcome and the effect of genetic polymorphisms on the incidence of hepatotoxicity","volume":"20","author":"Mathews","year":"2006","journal-title":"Leukemia."},{"issue":"15","key":"10.1016\/j.taap.2020.115299_bb0170","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJMc1309895","article-title":"Treatment of acute promyelocytic leukemia","volume":"369","author":"Miura","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.taap.2020.115299_bb0175","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2016.67.1982","article-title":"Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial","volume":"35","author":"Platzbecker","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.taap.2020.115299_bb0180","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2011.048","article-title":"Differentiation syndrome in promyelocytic leukemia: clinical presentation, pathogenesis and treatment","volume":"3","author":"Rego","year":"2011","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"issue":"33","key":"10.1016\/j.taap.2020.115299_bb0185","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1200\/JCO.2013.51.2913","article-title":"Prevalence, management, and clinical consequences of QT interval prolongation during treatment with arsenic trioxide","volume":"32","author":"Roboz","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.taap.2020.115299_bb0190","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1182\/blood.V89.9.3354","article-title":"Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients","volume":"89","author":"Shen","year":"1997","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.taap.2020.115299_bb0195","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.taap.2009.03.014","article-title":"Role of aquaporin 9 in cellular accumulation of arsenic and its cytotoxicity in primary mouse hepatocytes","volume":"237","author":"Shinkai","year":"2009","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"18","key":"10.1016\/j.taap.2020.115299_bb0200","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1200\/JCO.2001.19.18.3852","article-title":"United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia","volume":"19","author":"Soignet","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.taap.2020.115299_bb0205","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/bjh.16151","article-title":"Differentiation syndrome in acute promyelocytic leukaemia","volume":"187","author":"Stahl","year":"2019","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.taap.2020.115299_bb0215","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.ccell.2017.10.002","article-title":"Acute Promyelocytic leukemia: a paradigm for Oncoprotein-targeted cure","volume":"32","author":"de Th\u00e9","year":"2017","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.taap.2020.115299_bb0220","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1182\/blood-2007-07-102798","article-title":"Acute promyelocytic leukemia: from highly fatal to highly curable","volume":"111","author":"Wang","year":"2008","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.taap.2020.115299_bb0225","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1021\/tx0341714","article-title":"Arsenic speciation in urine from acute promyelocytic leukemia patients undergoing arsenic trioxide treatment","volume":"17","author":"Wang","year":"2004","journal-title":"Chem. Res. Toxicol."},{"issue":"12","key":"10.1016\/j.taap.2020.115299_bb0230","doi-asserted-by":"crossref","first-page":"4826","DOI":"10.1073\/pnas.0712365105","article-title":"Dissection of mechanisms of Chinese medicinal formula Realgar-indigo naturalis as an effective treatment for promyelocytic leukemia","volume":"105","author":"Wang","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.taap.2020.115299_bb0235","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1021\/tx500286t","article-title":"Effect of arsenic compounds on the in vitro differentiation of mouse embryonic stem cells into cardiomyocytes","volume":"28","author":"Wang","year":"2015","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.taap.2020.115299_bb0240","doi-asserted-by":"crossref","unstructured":"Wang, Q. Q., Zhou, X. Y., Zhang, Y. F., Bu, N., Zhou, J., Cao, F. L., Naranmandura, H., 2015b. Methylated arsenic metabolites bind to PML protein but do not induce cellular differentiation and PML-RAR\u03b1 protein degradation. Oncotarget. 6(28), 25646\u201325659. Doi: 10.18632\/oncotarget.4662.","DOI":"10.18632\/oncotarget.4662"},{"issue":"3","key":"10.1016\/j.taap.2020.115299_bb0245","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1039\/c9mt00308h","article-title":"Therapeutic strategy of arsenic trioxide in the fight against cancers and other diseases","volume":"12","author":"Wang","year":"2020","journal-title":"Metallomics."},{"issue":"3","key":"10.1016\/j.taap.2020.115299_bb0250","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jep.2011.03.071","article-title":"The medicinal use of realgar (as\u2084S\u2084) and its recent development as an anticancer agent","volume":"135","author":"Wu","year":"2011","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.taap.2020.115299_bb0255","first-page":"7","volume":"4","author":"Zhang","year":"1979","journal-title":"Heilongjiang Med. Pharm."},{"issue":"49","key":"10.1016\/j.taap.2020.115299_bb0260","doi-asserted-by":"crossref","first-page":"7146","DOI":"10.1038\/sj.onc.1204762","article-title":"Arsenic trioxide, a therapeutic agent for APL","volume":"20","author":"Zhang","year":"2001","journal-title":"Oncogene."},{"issue":"5975","key":"10.1016\/j.taap.2020.115299_bb0265","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1126\/science.1183424","article-title":"Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML","volume":"328","author":"Zhang","year":"2010","journal-title":"Science."},{"key":"10.1016\/j.taap.2020.115299_bb0270","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.yrtph.2018.09.010","article-title":"A review on arsenic carcinogenesis: epidemiology, metabolism, genotoxicity and epigenetic changes","volume":"99","author":"Zhou","year":"2018","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"33","key":"10.1016\/j.taap.2020.115299_bb0275","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1200\/JCO.2013.48.8312","article-title":"Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial","volume":"31","author":"Zhu","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.taap.2020.115299_bb0280","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1182\/blood-2016-02-699439","article-title":"The 12-year follow-up of survival, chronic adverse effects, and retention of arsenic in patients with acute promyelocytic leukemia","volume":"128","author":"Zhu","year":"2016","journal-title":"Blood."},{"issue":"7","key":"10.1016\/j.taap.2020.115299_bb0285","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S1470-2045(18)30295-X","article-title":"Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet. Oncol."},{"issue":"7","key":"10.1016\/j.taap.2020.115299_bb0290","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1182\/blood.2019000760","article-title":"The simpler, the better: oral arsenic for acute promyelocytic leukemia","volume":"134","author":"Zhu","year":"2019","journal-title":"Blood."}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X20304257?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X20304257?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T20:54:50Z","timestamp":1758574490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X20304257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":57,"alternative-id":["S0041008X20304257"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2020.115299","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Balance between the toxicity and anticancer activity of arsenic trioxide in treatment of acute promyelocytic leukemia","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2020.115299","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"115299"}}